This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Originally approved to help people with Type 2 diabetes, the class of medications known as GLP-1 agonists and dual GIP/GLP-1s quickly acquired a reputation for helping people shed stubborn pounds. As a result, the use of medications like Ozempic , Wegovy , Zepbound , Rybelsus , and Mounjaro has skyrocketed, as people turned to these medications to help them lose weightcausing drug shortages and creating a market for compounded versions of these brand-name drugs.
CVS Health was accused of contributing to a nationwide epidemic of opioid addiction and overdose by filling illegal opioid prescriptions and billing federal health insurance programs, according to a lawsuit unsealed Wednesday by the U.S. Department of Justice. The lawsuit alleged that, since October 2013, CVS knowingly filled prescriptions for “dangerous and excessive quantities” of controlled substances that lacked a legitimate medical purpose, were not valid, and were not issued
Tens of millions of people start their day with coffee without a second thoughtmany even find it difficult to have any thoughts at all before their first cup. But if youre taking prescription drugs on a regular basis, such as Linzess (the brand name for linaclotide), you may be wondering if you need to rethink your morning joe. Linzess is an oral medication that is approved by the Food and Drug Administration for the treatment of irritable bowel syndrome with constipation (IBS-C) as well as chro
Most of the formularies run by some of the largest health plans in the U.S. generally provide “fair access” to 11 treatments for several serious diseases, although transparent coverage information is often lacking for some medicines, a new analysis has found. Almost uniformly, the 11 formularies made the drugs available fairly when judged on three criteria: eligibility based on clinical data, restrictions placed on prescribers, and step therapy, which requires patients to try other
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
With the life sciences and healthcare sectors increasing integration of artificial intelligence (AI) into their infrastructure, according to research by GlobalData, one-third of healthcare professionals considered data privacy is the primary obstacle, citing challenges such as robust safeguards, workflow integration, and stakeholder acceptance [being] essential to ensure AIs ethical implementation and long-term success. 1 These concerns are held alongside the promise of this technology and its p
Top of the morning to you, and a fine one it is. Clear blue skies and chilly breezes are wafting across the Pharmalot campus, where the official mascots are snoozing after foraging for their breakfast. This means we are free to focus on the matters at hand — rummaging through our to-do list and making cups of stimulation. Our choice today is blueberry cobbler.
The FDA has doubled down on its decision to remove Eli Lillys tirzepatide from its list of products that are in shortage. | The FDA has doubled down on its decision to remove Eli Lillys tirzepatide from its list of products that are in shortage. The agencys move means that compounding pharmacies will have to halt production of their knockoff versions of diabetes drug Mounjaro and obesity treatment Zepbound.
The FDA has doubled down on its decision to remove Eli Lillys tirzepatide from its list of products that are in shortage. | The FDA has doubled down on its decision to remove Eli Lillys tirzepatide from its list of products that are in shortage. The agencys move means that compounding pharmacies will have to halt production of their knockoff versions of diabetes drug Mounjaro and obesity treatment Zepbound.
The Food and Drug Administration on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will soon put a stop to companies making cheaper copies of the injection. The agency said it would give these compounders a grace period of 60 to 90 days before enforcing rules that would put a halt to their work, in an effort to avoid disruption for patients.
Culina Health, a telenutrition company, raised $7.9 million in a series A funding round led by Healthworx, the innovation and investment arm ofCareFirst BlueCross BlueShield, the co | Four year-old Culina Health has raised its series A funding round, led by Healthworx, the venture arm of CareFirst. The company seeks to normalize nutrition counseling and prove that a better diet lowers total cost of care.
WASHINGTON — House Republicans have abandoned an effort to include reforms to pharmacy benefit managers in an end-of-year bill to fund the federal government. Congressional leaders had reached a deal to rein in prescription drug middlemen earlier this week, but the larger package it was tacked onto fell apart following backlash from conservatives and top advisers to President-elect Trump.
Medical equipment and supply manufacturer Medline Industries confidentially submitted plans for a proposed initial public offering, potentially setting the stage for a blockbuster public debut next | Medical equipment and supply manufacturer Medline Industries confidentially submitted plans for a proposed initial public offering, potentially setting the stage for a blockbuster public debut next year.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Elon Musk’s gift to PBMs? The year-end government funding bill was still in jeopardy as of the writing of this newsletter.
19 December 2024 London, UK, Menarini Stemline UK today welcomed final draft guidance from the National Institute for Health and Care Excellence(NICE) recommending use of the first tailored treatment for locally advanced and metastatic breast cancer that has acquired mutations in the ESR1gene, estimated to benefit around 1,000 patients in England and Wales each […] The post NICE recommendation for KORSERDU(elacestrant) marks step-change in the treatment of ESR1-mutated metastatic breast c
Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the end of January, alarming community activists who worry the move will limit access and, consequently, impede nationwide efforts to combat the infectious disease. The list includes Truvada, a widely prescribed medicine that is used to treat and prevent HIV, but for which lower-cost generic versions are now available.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. This is my last newsletter this year. Meghana will be writing the one tomorrow, and then we will be off for the next two weeks. Wishing everyone happy holidays and I’ll see you in the new year.
Will a contrarian leader be good for the Food and Drug Administration? Which ATTR-CM drug will have the best launch? And what are the hosts making for their holiday dinners? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. STAT’s FDA reporter Lizzy Lawrence joins us to discuss her profile of Marty Makary, Trump’s nominee for FDA commissioner.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
The Justice Department has filed suit against CVS, alleging that the retail giant unlawfully dispensed opioid prescriptions. | The Justice Department has filed suit against CVS, alleging that the retail giant unlawfully dispensed opioid prescriptions.
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses key risk factors for hypoglycemia and what education programs should emphasize so people with diabetes and their caregivers can improve its management.
Pharmaceutical corporations claim high prices are the cost of innovation, but the reality is far more complicated and troubling. In 2030, the patents of some of the worlds best-selling drugs will expire, an event called the 'patent cliff', and companies are doubling down on tactics such as 'evergreening' patents and pay-for-delay deals to keep prices high and competition out.
As we approach the end of 2024, First Opinion is publishing a series of essays on the state of AI in medicine and biopharma. “ How far away was Oswald from Kennedy? ” “ Major depressive disorder.
Following in the footsteps of several Big Pharma companies, another ALK inhibitor has made its entry into the U.S. | Following in the footsteps of Pfizer, Roche and Takeda, another ALK inhibitor has made its belated entry into the U.S. The FDA nod comes four years after its initial approval in China.
Discover how implementing a healthy and effective search strategy, focusing on Google, can significantly boost growth and success for pharmaceutical brands.
Explore how small molecule-focused Contract Development and Manufacturing Organisations (CDMOs) are adapting to the impact of the Inflation Reduction Act (IRA), shifting legislative landscape, and changes in the investment landscape.
Pharmacy professionals deserve the right to pursue mental health care without fear of losing their jobs. The Wellbeing First Champion Challenge is helping change this.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content